Cargando…

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

In recent years, immune checkpoint inhibitors (ICIs) targeting CTLA-4 or PD1/PDL1 have achieved remarkable success in the treatment of bladder cancer (BLCA), but only a few patients have shown durable clinical benefits. The prognostic role of a mutant form of the tumor suppressor gene TP53 (TP53-MT)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyu, Qiong, Lin, Anqi, Cao, Manming, Xu, Abai, Luo, Peng, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480364/ https://www.ncbi.nlm.nih.gov/pubmed/33356494 http://dx.doi.org/10.1177/1073274820976665

Ejemplares similares

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
por: Yi, Ruibin, et al.
Publicado: (2020)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
por: Manzano, Ramon Gonzalez, et al.
Publicado: (2021)

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy
por: Pan, Yi-Hui, et al.
Publicado: (2021)

Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration
por: Guan, Rui, et al.
Publicado: (2021)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
por: Cao, Jia-Zheng, et al.
Publicado: (2022)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

Spontaneous and inherited TP53 genetic alterations
por: Levine, Arnold J.
Publicado: (2021)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma
por: Li, Xinyi, et al.
Publicado: (2023)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

Alterations of the TP53 Gene in Gastric and Esophageal Carcinogenesis
por: Bellini, Marilanda Ferreira, et al.
Publicado: (2012)

Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma
por: Zhang, Yueming, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

A TP53-based immune prognostic model for muscle-invasive bladder cancer
por: Li, Hongyan, et al.
Publicado: (2020)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 alterations in relapsed childhood acute lymphoblastic leukemia
por: Yu, Chih‐Hsiang, et al.
Publicado: (2019)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
por: Stieg, David C., et al.
Publicado: (2023)

A Novel ATM/TP53/p21-Mediated Checkpoint Only Activated by Chronic γ-Irradiation
por: Cao, Lili, et al.
Publicado: (2014)

Early TP53 Alterations Shape Gastric and Esophageal Cancer Development
por: Sahgal, Pranshu, et al.
Publicado: (2021)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Genetic Variation in the TP53 Pathway and Bladder Cancer Risk. A Comprehensive Analysis
por: Pineda, Silvia, et al.
Publicado: (2014)

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
por: Li, Junjie, et al.
Publicado: (2021)

TP53 mutation status: emerging biomarker for precision radiation medicine?
por: Willers, Henning, et al.
Publicado: (2018)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk
por: Eiholzer, Ramona A., et al.
Publicado: (2020)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
por: Yang, Y C, et al.
Publicado: (2006)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

High mutations in fatty acid metabolism contribute to a better prognosis of small‐cell lung cancer patients treated with chemotherapy
por: Lyu, Qiong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aahttkcabcpck1ge6j4dtut83m